---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-455762"
form_type: "8-K"
ticker: "RLYB"
cik: "0001739410"
company_name: "Rallybio Corp"
filed_at: "2026-11-10T22:20:38+00:00"
generated_at: "2026-11-10T22:22:10.002201+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Rallybio sets 1-for-2 reverse stock split effective Nov. 20 ahead of Avenzo merger

## Summary
- Board approved a one-for-two reverse split on Nov. 8, 2026; effective 12:01 a.m. ET on Nov. 20, 2026, before the anticipated merger close.
- Issued and outstanding shares will fall from about 5.6 million to about 2.8 million; authorized shares and $0.0001 par value remain unchanged.
- After Nasdaq approvals and merger close, Rallybio plans to rename itself Avenzo Therapeutics and trade under ticker "AVZO" with CUSIP 053928 107.
- Merger agreement dated May 31, 2026 with Avenzo Therapeutics and Farmington Merger Sub; stockholders approved a split range of 1-for-2 to 1-for-9 on Nov. 4.
- No fractional shares will be issued; holders will receive cash equal to fair market value based on the closing price on the split's effective date, with Computershare as exchange agent.

## SEC filing metadata
- accession: 0001193125-26-455762
- form_type: 8-K
- ticker: RLYB
- cik: 0001739410
- company_name: Rallybio Corp
- filed_at: 2026-11-10T22:20:38+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739410/000119312526455762/0001193125-26-455762-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739410/000119312526455762/d162317d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-455762
- JSON: https://secwatch.observer/filing/0001193125-26-455762.json
- Plain text: https://secwatch.observer/filing/0001193125-26-455762.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.